What is the Sun Pharma Advanced Research PE ratio today?
Sun Pharma Advanced Research's PE ratio is 3.7 at the 29 October 2026 close (₹182.98 a share): a market capitalisation of ₹5,938 crore divided by consolidated net profit of ₹1,586 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹1,556 crore) it is 3.8.
What is the Sun Pharma Advanced Research PB ratio (price to book value)?
Sun Pharma Advanced Research's price-to-book (PB) ratio is 4.44 at the 29 October 2026 close: a market capitalisation of ₹5,938 crore divided by shareholders' equity (book value) of ₹1,339 crore on 31 March 2026. That is a book value of ₹41.26 per share against a share price of ₹182.98.
What is the Sun Pharma Advanced Research net worth?
Sun Pharma Advanced Research's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,339 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹5,938 crore at the 29 October 2026 close.
What is the Sun Pharma Advanced Research market cap?
Sun Pharma Advanced Research's market capitalisation was ₹5,938 crore at the 29 October 2026 close: 32.45 crore shares at ₹182.98 each.
Is Sun Pharma Advanced Research debt free?
No. Sun Pharma Advanced Research had borrowings of ₹556 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.42. Its cash and current investments were ₹1.2 crore, so its net debt was ₹555 crore.
What is the Sun Pharma Advanced Research debt to equity ratio?
Sun Pharma Advanced Research's debt-to-equity ratio was 0.42 on 31 March 2026: borrowings of ₹556 crore against total equity of ₹1,339 crore. A year earlier, on 31 March 2025, it was -1.19.
What is the Sun Pharma Advanced Research book value per share?
Sun Pharma Advanced Research's book value per share was ₹41.26 on 31 March 2026: shareholders' equity of ₹1,339 crore divided by the 32.45 crore shares in issue. The share price at the 29 October 2026 close was ₹182.98.
What is the Sun Pharma Advanced Research promoter holding?
Promoters held 65.67% of Sun Pharma Advanced Research on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Sun Pharma Advanced Research revenue and profit in FY26?
In FY26 (April 2025–March 2026), Sun Pharma Advanced Research's consolidated net profit was ₹1,556 crore, against a loss of ₹343 crore in FY25, on revenue from operations of ₹1,879 crore.
What is the Sun Pharma Advanced Research EPS?
Sun Pharma Advanced Research's basic earnings per share (EPS) were ₹47.86 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹48.81.
What is the Sun Pharma Advanced Research free cash flow?
In FY26, Sun Pharma Advanced Research generated ₹239 crore of cash from operations and spent ₹23.8 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹263 crore. In FY25 it was −₹371 crore.
When are the Sun Pharma Advanced Research next results?
Sun Pharma Advanced Research will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.
What is the Sun Pharma Advanced Research shareholding pattern?
On 30 September 2026, Sun Pharma Advanced Research's shares were held by promoters 65.67%, foreign portfolio investors (FII/FPI) 3.75%, domestic institutions (DII) 0.11% (including mutual funds at 0.10%) and retail and other non-institutional investors 30.48%. Over the year, FII holding was up 1.99 percentage points from 1.76% and DII holding was down 0.94 percentage points from 1.05%.
How does Sun Pharma Advanced Research compare with its peers?
On FY26 consolidated figures, against Strides Pharma Science and Shilpa Medicare: Sun Pharma Advanced Research's operating margin of 84.5% is the highest of the three (Strides Pharma Science 14.9%, Shilpa Medicare 20.5%; peer average 17.7%); its revenue growth over three years of 96.0% a year is the highest of the three (Strides Pharma Science 9.6% a year, Shilpa Medicare 13.6% a year; peer average 11.6% a year).
Sun Pharma Advanced Research vs Strides Pharma Science: how do they compare?
In FY26, Sun Pharma Advanced Research earned net profit of ₹1,556 crore on revenue of ₹1,879 crore, against ₹556 crore on ₹4,859 crore for Strides Pharma Science. Sun Pharma Advanced Research's operating margin was 84.5% (Strides Pharma Science 14.9%). At the 29 October 2026 close, Sun Pharma Advanced Research's market capitalisation was ₹5,938 crore against ₹10,116 crore for Strides Pharma Science, and its PE ratio on FY26 profit 3.8 against 18.2.
What are the Sun Pharma Advanced Research latest quarterly results?
Sun Pharma Advanced Research's latest results are for Q1 FY27 (April–June 2026), filed on 10 August 2026: consolidated net loss ₹20.8 crore, narrower than the loss of ₹51.9 crore in Q1 FY26; revenue from operations ₹39.9 crore, up 314.1% year on year.
How does the Sun Pharma Advanced Research PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Sun Pharma Advanced Research's PE ratio is 3.8, the lowest of the three: Strides Pharma Science 18.2 and Shilpa Medicare 75.2, a peer average of 46.7. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
